查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2158726

IL-12受體拮抗劑市場：全球市場預測，2026-2032年

IL-12 Receptor Antagonist Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，IL-12 受體拮抗劑市場將成長至 5.2484 億美元，複合年成長率為 8.94%。

主要市場統計數據
基準年 2025 2.8818億美元
預計年份：2026年 3.1422億美元
預測年份 2032 5.2484億美元
複合年成長率 (%) 8.94%

IL-12受體拮抗劑：概述

IL-12受體拮抗劑是一類新型免疫調節療法，旨在阻斷與白細胞介素-12活性相關的訊號傳導。 IL-12在T細胞和自然殺手細胞活化、干擾素-γ產生以及發炎免疫反應中發揮重要作用，因此IL-12受體拮抗劑至關重要。在免疫介導疾病整體， IL-12受體拮抗劑的研發工作需要在有效調節免疫功能、降低感染風險、減輕給藥負擔以及滿足實證醫學要求之間取得平衡。

從廣泛的免疫抑製到靶向細胞激素調控

治療趨勢正朝著更具選擇性的細胞激素路徑干預、基於生物標記的患者篩選以及旨在維持保護性免疫的治療策略方向發展。對於IL-12受體拮抗劑而言，這為透過通路特異性、給藥便捷性、持續療效以及在對現有生物製藥反應不佳或不耐受的患者群體中的應用來實現差異化提供了機會。監管環境也日益重視具有臨床意義的療效、安全性評估以及來自不同患者群體的證據。

人工智慧（AI）正在加速藥物發現、開發和治療過程。

人工智慧可以透過識別免疫反應模式、確定治療標靶優先順序、最佳化抗體和蛋白質設計以及改善複雜臨床數據的解讀，對該領域產生深遠影響。在研發計畫中，機器學習技術可以輔助臨床試驗受試者招募的可行性評估、終點分析、安全性訊號偵測以及反應亞組的辨識。其應用不僅應基於演算法的效能，還應基於資料品質、可解釋性、隱私保護、前瞻性檢驗以及明確的臨床課責。

區域洞察：監管、准入和轉化能力方面的差異

北美擁有強大的生物醫學研究能力、完善的生技藥品開發基礎設施和嚴格的證據標準。歐洲則強調合作監管科學、醫療技術評估和臨床價值比較，歐盟也增加了臨床試驗進行和准入的跨國考量。亞太地區的臨床、生產和轉化研究能力正在不斷提升，尤其是在日本、中國、韓國、澳洲和印度。拉丁美洲由於專業醫療體系的擴張而蘊藏著機遇，但需要考慮不同的報銷機制和臨床試驗的後勤物流。中東的特徵是醫療投資集中，且各國採購體系各自獨立；而非洲則需要製定適應不同地區在專科醫生資源、診斷基礎設施和感染疾病方面差異的策略。

集團洞察：貿易集團與聯盟塑造發展策略

在東協市場，各成員國的監管路徑、報銷機制和專科醫療體系各不相同，因此需要採取因國而異的策略。金磚國家在智慧財產權、採購和證據方面存在差異，科學和臨床方面也存在顯著差異。儘管歐盟支持聯合調查和協調一致的監管措施，但具體的報銷決策仍然至關重要。七國集團成員國通常擁有成熟的臨床基礎設施和嚴格的證據要求。海灣合作理事會成員國可以利用集中採購管道和資源充足的專科醫療中心。北約成員國的醫療體系各不相同，加入北約遠不如各國自身的監管、資金籌措和臨床網路的成熟度重要。

國家概況：當地證據和准入條件仍然至關重要。

澳洲支持先進的臨床研究和受監管生技藥品的獲取，而巴西和墨西哥則需要有效利用多元化的公共和私人醫療管道。加拿大擁有強大的研究機構，同時中央和省級政府也對生物製劑的取得給予了充分的考慮。中國正在其自身的監管和報銷體系下拓展生物醫學能力。印度擁有廣泛的臨床資源，但取得條件差異很大。日本和韓國維持著高度專業化的醫療體系，並有各自特定的證據要求。法國、德國、義大利、西班牙和英國則要求與國家和地區的評估流程保持一致。俄羅斯擁有其獨特的監管和營運環境。在美國，差異化的臨床證據、與保險公司的合作以及醫生的採納是生物製劑普及的關鍵。

領導者的優先事項：建立證據基礎、增強韌性、提升與病人的相關性

產業領導者應明確具體的臨床應用案例，儘早建立轉化生物標記物，並設計能夠同時證明療效和臨床相關安全性的臨床試驗。研發計畫應涵蓋不同地區，產生可操作的證據，並與現有的免疫調節療法形成明確的區分。生產和供應策略必須應對生物製藥的複雜性、品質一致性、冷鏈要求以及應對地緣政治風險的能力。此外，各組織應正式建立負責任的人工智慧管治，儘早與監管機構和衛生技術評估機構接洽，並制定反映國家醫保體系和診斷實際情況的准入計畫。

調查方法：從科學、監管和獲取三個面向進行證據三角驗證。

本執行摘要系統地整合了與IL-12受體拮抗劑相關的公開檢驗的科學、臨床、監管和醫療保健系統證據。評估考慮了生物證據、治療研發模式、安全性和證據要求、區域商業環境以及群體和國家層面的進入因素。解釋採用定性方法，避免未經證實的市場估算、預測、市場佔有率、展望或公司特定聲明。隨著臨床結果、監管決策、治療指南和報銷政策的演變，這些結論應定期更新。

結論：選擇性免疫調節需要精準執行。

IL-12受體拮抗劑是免疫路徑標靶調控這一大趨勢的一部分。它們的潛力取決於能否展現明確的治療作用、維持可接受的安全性，以及將機制特異性選擇性轉化為對患者、臨床醫生、監管機構和支付方都至關重要的治療結果。成功需要嚴謹的證據收集、基於本地的准入規劃、合理運用人工智慧，以及持續關注生產和醫療保健系統的基礎設施。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 IL-12受體拮抗劑市場：依適應症分類

  • 克隆氏症
  • 銀屑病
  • 乾癬性關節炎
  • 潰瘍性大腸炎

第8章：IL-12受體拮抗劑市場：依給藥途徑分類

  • 靜脈輸液
  • 皮下注射
    • 自動注射器
    • 預填充式注射器

第9章：IL-12受體拮抗劑市場：按劑型分類

  • 自動注射器
  • 凍乾粉
  • 預填充式注射器
  • 解決方案

第10章：IL-12受體拮抗劑市場：依患者年齡層別分類

  • 成人
  • 老年人
  • 兒童

第11章 IL-12受體拮抗劑市場：依劑量強度分類

  • 高劑量
  • 低劑量
  • 中等劑量

第12章 IL-12受體拮抗劑市場：依最終用戶分類

  • 門診部
  • 居家照護
  • 醫院
  • 專科診所

第13章：IL-12受體拮抗劑市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第14章 IL-12受體拮抗劑市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第15章 IL-12受體拮抗劑市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 IL-12受體拮抗劑市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 2025年市佔率分析
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第18章：公司簡介

  • AbbVie Inc.
  • AI Therapeutics, Inc.
  • Akeso, Inc.
  • Alaunos Therapeutics, Inc.
  • Alvotech hf.
  • Amgen Inc.
  • AstraZeneca PLC
  • BioInvent International AB
  • Boehringer Ingelheim International GmbH
  • Cipla Limited
  • ESSA Pharma Inc.
  • Fuji Pharma Co., Ltd.
  • Janssen Pharmaceutica NV
  • Madrigal Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Samsung Bioepis Co., Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Tourmaline Bio, Inc.
  • VBL Therapeutics Ltd.
  • Ventyx Biosciences, Inc.

第19章 主要專家

Product Code: MRR-4654A89DBBB1

The IL-12 Receptor Antagonist Market is projected to grow by USD 524.84 million at a CAGR of 8.94% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 288.18 million
Estimated Year [2026] USD 314.22 million
Forecast Year [2032] USD 524.84 million
CAGR (%) 8.94%

IL-12 Receptor Antagonists: Executive Overview

IL-12 receptor antagonists are an emerging class of immunomodulatory therapies designed to interrupt signaling associated with interleukin-12 activity. Their relevance is rooted in the role of IL-12 in T-cell and natural-killer-cell activation, interferon-gamma production, and inflammatory immune responses. Development activity is shaped by the need to balance meaningful immune modulation with infection risk, administration burden, and evidence requirements across immune-mediated diseases.

From Broad Immunosuppression to Targeted Cytokine Modulation

The therapeutic landscape is shifting toward more selective cytokine pathway intervention, biomarker-informed patient selection, and treatment strategies that aim to preserve protective immunity. For IL-12 receptor antagonists, this creates opportunities to differentiate through pathway specificity, dosing convenience, durable response, and positioning in patients who have inadequate responses or intolerance to established biologic approaches. Regulatory expectations increasingly emphasize clinically meaningful outcomes, safety characterization, and evidence across diverse patient populations.

Artificial Intelligence Accelerates Discovery, Development, and Care Pathways

Artificial intelligence can influence the field by identifying immune-response patterns, prioritizing therapeutic targets, optimizing antibody or protein design, and improving the interpretation of complex clinical data. In development programs, machine-learning methods may support trial-enrollment feasibility, endpoint analysis, safety-signal detection, and identification of response subgroups. Adoption should remain governed by data quality, explainability, privacy safeguards, prospective validation, and clear clinical accountability rather than by algorithmic performance alone.

Regional Insights: Regulation, Access, and Translational Capacity Differ

North America combines strong biomedical research capacity with sophisticated biologic-development infrastructure and demanding evidence standards. Europe emphasizes coordinated regulatory science, health-technology assessment, and comparative clinical value, while the European Union adds cross-border considerations for trial execution and access. Asia-Pacific offers expanding clinical, manufacturing, and translational capabilities, particularly across Japan, China, South Korea, Australia, and India. Latin America presents opportunities linked to rising specialty-care capacity but requires attention to reimbursement variation and trial logistics. The Middle East is shaped by concentrated healthcare investment and varying national procurement systems, while Africa requires strategies adapted to uneven specialist access, diagnostic infrastructure, and infectious-disease considerations.

Group Insights: Trade Blocs and Alliances Shape Development Strategy

ASEAN markets require country-sensitive approaches because regulatory pathways, reimbursement systems, and specialist capacity differ across members. BRICS economies offer substantial scientific and clinical diversity, alongside varied intellectual-property, procurement, and evidence environments. The European Union supports collaborative research and coordinated regulatory engagement, although national reimbursement decisions remain important. G7 members generally provide mature clinical infrastructure and stringent evidence expectations. GCC countries can offer centralized procurement opportunities and well-resourced specialty-care hubs. NATO members span diverse healthcare systems, making alliance membership less determinative than national regulation, funding, and clinical-network readiness.

Country Insights: Local Evidence and Access Conditions Remain Decisive

Australia supports advanced clinical research and regulated biologic access, while Brazil and Mexico require navigation of diverse public and private healthcare channels. Canada combines strong research institutions with centralized and provincial access considerations. China is expanding biomedical capabilities under a distinct regulatory and reimbursement environment; India offers broad clinical depth but highly variable access conditions. Japan and South Korea maintain advanced specialty-care systems with country-specific evidence expectations. France, Germany, Italy, Spain, and the United Kingdom require alignment with national and regional assessment processes. Russia presents a distinct regulatory and operating context. In the United States, differentiated clinical evidence, payer engagement, and physician adoption are central to uptake.

Priorities for Leaders: Build Evidence, Resilience, and Patient Relevance

Industry leaders should define a focused clinical use case, establish translational biomarkers early, and design trials that demonstrate both efficacy and clinically relevant safety. Development plans should incorporate diverse geographies, pragmatic evidence generation, and clear differentiation from existing immune-modulating options. Manufacturing and supply strategies should address biologic complexity, quality consistency, cold-chain requirements, and geopolitical resilience. Organizations should also formalize responsible-AI governance, engage regulators and health-technology assessors early, and develop access plans that reflect country-level reimbursement and diagnostic realities.

Methodology: Evidence Triangulation Across Science, Regulation, and Access

This executive summary uses a structured synthesis of publicly verifiable scientific, clinical, regulatory, and healthcare-system evidence relevant to IL-12 receptor antagonists. The assessment considers biological rationale, therapeutic-development patterns, safety and evidence requirements, regional operating conditions, and group- and country-level access factors. Interpretations are framed qualitatively and avoid unsupported market estimates, market shares, forecasts, or company-specific claims. Findings should be refreshed as clinical readouts, regulatory decisions, treatment guidelines, and reimbursement policies evolve.

Conclusion: Selective Immunomodulation Requires Precise Execution

IL-12 receptor antagonists sit within a broader movement toward targeted immune-pathway control. Their prospects depend on demonstrating a clear therapeutic role, maintaining an acceptable safety profile, and translating mechanistic selectivity into outcomes valued by patients, clinicians, regulators, and payers. Success will require disciplined evidence generation, regionally informed access planning, responsible use of artificial intelligence, and sustained attention to manufacturing and healthcare-system readiness.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. New Revenue Opportunities
  • 3.4. Next-Generation Business Models
  • 3.5. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. IL-12 Receptor Antagonist Market, by Indication

  • 7.1. Introduction
  • 7.2. Crohn Disease
  • 7.3. Psoriasis
  • 7.4. Psoriatic Arthritis
  • 7.5. Ulcerative Colitis

8. IL-12 Receptor Antagonist Market, by Route Of Administration

  • 8.1. Introduction
  • 8.2. Intravenous Infusion
  • 8.3. Subcutaneous Injection
    • 8.3.1. Auto Injector
    • 8.3.2. Prefilled Syringe

9. IL-12 Receptor Antagonist Market, by Form

  • 9.1. Introduction
  • 9.2. Auto Injector
  • 9.3. Lyophilized Powder
  • 9.4. Prefilled Syringe
  • 9.5. Solution

10. IL-12 Receptor Antagonist Market, by Patient Age Group

  • 10.1. Introduction
  • 10.2. Adult
  • 10.3. Geriatric
  • 10.4. Pediatric

11. IL-12 Receptor Antagonist Market, by Dosage Strength

  • 11.1. Introduction
  • 11.2. High Dose
  • 11.3. Low Dose
  • 11.4. Medium Dose

12. IL-12 Receptor Antagonist Market, by End User

  • 12.1. Introduction
  • 12.2. Ambulatory Care Centers
  • 12.3. Home Care
  • 12.4. Hospitals
  • 12.5. Specialty Clinics

13. IL-12 Receptor Antagonist Market, by Distribution Channel

  • 13.1. Introduction
  • 13.2. Hospital Pharmacy
  • 13.3. Online Pharmacy
  • 13.4. Retail Pharmacy

14. IL-12 Receptor Antagonist Market, by Region

  • 14.1. Introduction
  • 14.2. Asia-Pacific
  • 14.3. North America
  • 14.4. Latin America
  • 14.5. Europe
  • 14.6. Middle East
  • 14.7. Africa

15. IL-12 Receptor Antagonist Market, by Group

  • 15.1. Introduction
  • 15.2. ASEAN
  • 15.3. GCC
  • 15.4. European Union
  • 15.5. BRICS
  • 15.6. G7
  • 15.7. NATO

16. IL-12 Receptor Antagonist Market, by Country

  • 16.1. Introduction
  • 16.2. United States
  • 16.3. Canada
  • 16.4. Mexico
  • 16.5. Brazil
  • 16.6. United Kingdom
  • 16.7. Germany
  • 16.8. France
  • 16.9. Russia
  • 16.10. Italy
  • 16.11. Spain
  • 16.12. China
  • 16.13. India
  • 16.14. Japan
  • 16.15. Australia
  • 16.16. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2025
  • 17.2. Market Concentration Analysis, 2025
    • 17.2.1. Concentration Ratio (CR)
    • 17.2.2. Herfindahl Hirschman Index (HHI)
  • 17.3. Recent Developments & Impact Analysis, 2025
  • 17.4. Product Portfolio Analysis, 2025
  • 17.5. Benchmarking Analysis, 2025

18. Company Profiles

  • 18.1. AbbVie Inc.
  • 18.2. AI Therapeutics, Inc.
  • 18.3. Akeso, Inc.
  • 18.4. Alaunos Therapeutics, Inc.
  • 18.5. Alvotech hf.
  • 18.6. Amgen Inc.
  • 18.7. AstraZeneca PLC
  • 18.8. BioInvent International AB
  • 18.9. Boehringer Ingelheim International GmbH
  • 18.10. Cipla Limited
  • 18.11. ESSA Pharma Inc.
  • 18.12. Fuji Pharma Co., Ltd.
  • 18.13. Janssen Pharmaceutica NV
  • 18.14. Madrigal Pharmaceuticals, Inc.
  • 18.15. Pfizer Inc.
  • 18.16. Samsung Bioepis Co., Ltd.
  • 18.17. Teva Pharmaceutical Industries Ltd.
  • 18.18. Tourmaline Bio, Inc.
  • 18.19. VBL Therapeutics Ltd.
  • 18.20. Ventyx Biosciences, Inc.

19. Key Experts

LIST OF FIGURES

  • FIGURE 1. Global IL-12 Receptor Antagonist Market, Years Considered for the Study
  • FIGURE 2. Global IL-12 Receptor Antagonist Market, Research Design
  • FIGURE 3. Global IL-12 Receptor Antagonist Market, Research Framework
  • FIGURE 4. Global IL-12 Receptor Antagonist Market, Data Triangulation
  • FIGURE 5. Global IL-12 Receptor Antagonist Market Size, 2017-2032 (USD Million)
  • FIGURE 6. Global IL-12 Receptor Antagonist Market Size, by Indication, 2025 vs 2032 (%)
  • FIGURE 7. Global IL-12 Receptor Antagonist Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 8. Global IL-12 Receptor Antagonist Market Size, by Route Of Administration, 2025 vs 2032 (%)
  • FIGURE 9. Global IL-12 Receptor Antagonist Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 10. Global IL-12 Receptor Antagonist Market Size, by Form, 2025 vs 2032 (%)
  • FIGURE 11. Global IL-12 Receptor Antagonist Market Size, by Form, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 12. Global IL-12 Receptor Antagonist Market Size, by Patient Age Group, 2025 vs 2032 (%)
  • FIGURE 13. Global IL-12 Receptor Antagonist Market Size, by Patient Age Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 14. Global IL-12 Receptor Antagonist Market Size, by Dosage Strength, 2025 vs 2032 (%)
  • FIGURE 15. Global IL-12 Receptor Antagonist Market Size, by Dosage Strength, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 16. Global IL-12 Receptor Antagonist Market Size, by End User, 2025 vs 2032 (%)
  • FIGURE 17. Global IL-12 Receptor Antagonist Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 18. Global IL-12 Receptor Antagonist Market Size, by Distribution Channel, 2025 vs 2032 (%)
  • FIGURE 19. Global IL-12 Receptor Antagonist Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 20. Global IL-12 Receptor Antagonist Market Size, by Region, 2025 vs 2032 (%)
  • FIGURE 21. Global IL-12 Receptor Antagonist Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 22. Global IL-12 Receptor Antagonist Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 23. Global IL-12 Receptor Antagonist Market Size, by Country, 2025 vs 2032 (%)
  • FIGURE 24. Global IL-12 Receptor Antagonist Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 25. Global IL-12 Receptor Antagonist Market Share, by Key Player, 2025

LIST OF TABLES

  • TABLE 1. Global IL-12 Receptor Antagonist Market Segmentation & Coverage
  • TABLE 2. Global IL-12 Receptor Antagonist Market Size, 2017-2032 (USD Million)
  • TABLE 3. Global IL-12 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 4. Global Crohn Disease Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 5. Global Crohn Disease Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 6. Global Crohn Disease Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 7. Global Psoriasis Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 8. Global Psoriasis Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 9. Global Psoriasis Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 10. Global Psoriatic Arthritis Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 11. Global Psoriatic Arthritis Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 12. Global Psoriatic Arthritis Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 13. Global Ulcerative Colitis Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 14. Global Ulcerative Colitis Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 15. Global Ulcerative Colitis Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 16. Global IL-12 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 17. Global Intravenous Infusion Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 18. Global Intravenous Infusion Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 19. Global Intravenous Infusion Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 20. Global Subcutaneous Injection Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 21. Global Subcutaneous Injection Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 22. Global Subcutaneous Injection Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 23. Global Auto Injector Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 24. Global Auto Injector Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 25. Global Auto Injector Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 26. Global Prefilled Syringe Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 27. Global Prefilled Syringe Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 28. Global Prefilled Syringe Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 29. Global IL-12 Receptor Antagonist Market Size, by Form, 2017-2032 (USD Million)
  • TABLE 30. Global Auto Injector Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 31. Global Auto Injector Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 32. Global Auto Injector Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 33. Global Lyophilized Powder Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 34. Global Lyophilized Powder Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 35. Global Lyophilized Powder Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 36. Global Prefilled Syringe Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 37. Global Prefilled Syringe Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 38. Global Prefilled Syringe Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 39. Global Solution Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 40. Global Solution Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 41. Global Solution Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 42. Global IL-12 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 43. Global Adult Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 44. Global Adult Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 45. Global Adult Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 46. Global Geriatric Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 47. Global Geriatric Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 48. Global Geriatric Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 49. Global Pediatric Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 50. Global Pediatric Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 51. Global Pediatric Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 52. Global IL-12 Receptor Antagonist Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 53. Global High Dose Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 54. Global High Dose Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 55. Global High Dose Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 56. Global Low Dose Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 57. Global Low Dose Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 58. Global Low Dose Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 59. Global Medium Dose Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 60. Global Medium Dose Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 61. Global Medium Dose Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 62. Global IL-12 Receptor Antagonist Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 63. Global Ambulatory Care Centers Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 64. Global Ambulatory Care Centers Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 65. Global Ambulatory Care Centers Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 66. Global Home Care Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 67. Global Home Care Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 68. Global Home Care Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 69. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 70. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 71. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 72. Global Specialty Clinics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 73. Global Specialty Clinics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 74. Global Specialty Clinics Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 75. Global IL-12 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 76. Global Hospital Pharmacy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 77. Global Hospital Pharmacy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 78. Global Hospital Pharmacy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 79. Global Online Pharmacy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 80. Global Online Pharmacy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 81. Global Online Pharmacy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 82. Global Retail Pharmacy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 83. Global Retail Pharmacy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 84. Global Retail Pharmacy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 85. Global IL-12 Receptor Antagonist Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 86. Asia-Pacific IL-12 Receptor Antagonist Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 87. Asia-Pacific IL-12 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 88. Asia-Pacific IL-12 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 89. Asia-Pacific IL-12 Receptor Antagonist Market Size, by Subcutaneous Injection, 2017-2032 (USD Million)
  • TABLE 90. Asia-Pacific IL-12 Receptor Antagonist Market Size, by Form, 2017-2032 (USD Million)
  • TABLE 91. Asia-Pacific IL-12 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 92. Asia-Pacific IL-12 Receptor Antagonist Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 93. Asia-Pacific IL-12 Receptor Antagonist Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 94. Asia-Pacific IL-12 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 95. North America IL-12 Receptor Antagonist Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 96. North America IL-12 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 97. North America IL-12 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 98. North America IL-12 Receptor Antagonist Market Size, by Subcutaneous Injection, 2017-2032 (USD Million)
  • TABLE 99. North America IL-12 Receptor Antagonist Market Size, by Form, 2017-2032 (USD Million)
  • TABLE 100. North America IL-12 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 101. North America IL-12 Receptor Antagonist Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 102. North America IL-12 Receptor Antagonist Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 103. North America IL-12 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 104. Latin America IL-12 Receptor Antagonist Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 105. Latin America IL-12 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 106. Latin America IL-12 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 107. Latin America IL-12 Receptor Antagonist Market Size, by Subcutaneous Injection, 2017-2032 (USD Million)
  • TABLE 108. Latin America IL-12 Receptor Antagonist Market Size, by Form, 2017-2032 (USD Million)
  • TABLE 109. Latin America IL-12 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 110. Latin America IL-12 Receptor Antagonist Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 111. Latin America IL-12 Receptor Antagonist Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 112. Latin America IL-12 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 113. Europe IL-12 Receptor Antagonist Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 114. Europe IL-12 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 115. Europe IL-12 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 116. Europe IL-12 Receptor Antagonist Market Size, by Subcutaneous Injection, 2017-2032 (USD Million)
  • TABLE 117. Europe IL-12 Receptor Antagonist Market Size, by Form, 2017-2032 (USD Million)
  • TABLE 118. Europe IL-12 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 119. Europe IL-12 Receptor Antagonist Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 120. Europe IL-12 Receptor Antagonist Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 121. Europe IL-12 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 122. Middle East IL-12 Receptor Antagonist Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 123. Middle East IL-12 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 124. Middle East IL-12 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 125. Middle East IL-12 Receptor Antagonist Market Size, by Subcutaneous Injection, 2017-2032 (USD Million)
  • TABLE 126. Middle East IL-12 Receptor Antagonist Market Size, by Form, 2017-2032 (USD Million)
  • TABLE 127. Middle East IL-12 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 128. Middle East IL-12 Receptor Antagonist Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 129. Middle East IL-12 Receptor Antagonist Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 130. Middle East IL-12 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 131. Africa IL-12 Receptor Antagonist Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 132. Africa IL-12 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 133. Africa IL-12 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 134. Africa IL-12 Receptor Antagonist Market Size, by Subcutaneous Injection, 2017-2032 (USD Million)
  • TABLE 135. Africa IL-12 Receptor Antagonist Market Size, by Form, 2017-2032 (USD Million)
  • TABLE 136. Africa IL-12 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 137. Africa IL-12 Receptor Antagonist Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 138. Africa IL-12 Receptor Antagonist Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 139. Africa IL-12 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 140. Global IL-12 Receptor Antagonist Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 141. ASEAN IL-12 Receptor Antagonist Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 142. ASEAN IL-12 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 143. ASEAN IL-12 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 144. ASEAN IL-12 Receptor Antagonist Market Size, by Subcutaneous Injection, 2017-2032 (USD Million)
  • TABLE 145. ASEAN IL-12 Receptor Antagonist Market Size, by Form, 2017-2032 (USD Million)
  • TABLE 146. ASEAN IL-12 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 147. ASEAN IL-12 Receptor Antagonist Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 148. ASEAN IL-12 Receptor Antagonist Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 149. ASEAN IL-12 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 150. GCC IL-12 Receptor Antagonist Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 151. GCC IL-12 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 152. GCC IL-12 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 153. GCC IL-12 Receptor Antagonist Market Size, by Subcutaneous Injection, 2017-2032 (USD Million)
  • TABLE 154. GCC IL-12 Receptor Antagonist Market Size, by Form, 2017-2032 (USD Million)
  • TABLE 155. GCC IL-12 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 156. GCC IL-12 Receptor Antagonist Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 157. GCC IL-12 Receptor Antagonist Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 158. GCC IL-12 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 159. European Union IL-12 Receptor Antagonist Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 160. European Union IL-12 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 161. European Union IL-12 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 162. European Union IL-12 Receptor Antagonist Market Size, by Subcutaneous Injection, 2017-2032 (USD Million)
  • TABLE 163. European Union IL-12 Receptor Antagonist Market Size, by Form, 2017-2032 (USD Million)
  • TABLE 164. European Union IL-12 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 165. European Union IL-12 Receptor Antagonist Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 166. European Union IL-12 Receptor Antagonist Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 167. European Union IL-12 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 168. BRICS IL-12 Receptor Antagonist Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 169. BRICS IL-12 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 170. BRICS IL-12 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 171. BRICS IL-12 Receptor Antagonist Market Size, by Subcutaneous Injection, 2017-2032 (USD Million)
  • TABLE 172. BRICS IL-12 Receptor Antagonist Market Size, by Form, 2017-2032 (USD Million)
  • TABLE 173. BRICS IL-12 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 174. BRICS IL-12 Receptor Antagonist Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 175. BRICS IL-12 Receptor Antagonist Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 176. BRICS IL-12 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 177. G7 IL-12 Receptor Antagonist Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 178. G7 IL-12 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 179. G7 IL-12 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 180. G7 IL-12 Receptor Antagonist Market Size, by Subcutaneous Injection, 2017-2032 (USD Million)
  • TABLE 181. G7 IL-12 Receptor Antagonist Market Size, by Form, 2017-2032 (USD Million)
  • TABLE 182. G7 IL-12 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 183. G7 IL-12 Receptor Antagonist Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 184. G7 IL-12 Receptor Antagonist Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 185. G7 IL-12 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 186. NATO IL-12 Receptor Antagonist Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 187. NATO IL-12 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 188. NATO IL-12 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 189. NATO IL-12 Receptor Antagonist Market Size, by Subcutaneous Injection, 2017-2032 (USD Million)
  • TABLE 190. NATO IL-12 Receptor Antagonist Market Size, by Form, 2017-2032 (USD Million)
  • TABLE 191. NATO IL-12 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 192. NATO IL-12 Receptor Antagonist Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 193. NATO IL-12 Receptor Antagonist Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 194. NATO IL-12 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 195. Global IL-12 Receptor Antagonist Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 196. United States IL-12 Receptor Antagonist Market Size, 2017-2032 (USD Million)
  • TABLE 197. United States IL-12 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 198. United States IL-12 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 199. United States IL-12 Receptor Antagonist Market Size, by Subcutaneous Injection, 2017-2032 (USD Million)
  • TABLE 200. United States IL-12 Receptor Antagonist Market Size, by Form, 2017-2032 (USD Million)
  • TABLE 201. United States IL-12 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 202. United States IL-12 Receptor Antagonist Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 203. United States IL-12 Receptor Antagonist Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 204. United States IL-12 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 205. Canada IL-12 Receptor Antagonist Market Size, 2017-2032 (USD Million)
  • TABLE 206. Canada IL-12 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 207. Canada IL-12 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 208. Canada IL-12 Receptor Antagonist Market Size, by Subcutaneous Injection, 2017-2032 (USD Million)
  • TABLE 209. Canada IL-12 Receptor Antagonist Market Size, by Form, 2017-2032 (USD Million)
  • TABLE 210. Canada IL-12 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 211. Canada IL-12 Receptor Antagonist Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 212. Canada IL-12 Receptor Antagonist Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 213. Canada IL-12 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 214. Mexico IL-12 Receptor Antagonist Market Size, 2017-2032 (USD Million)
  • TABLE 215. Mexico IL-12 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 216. Mexico IL-12 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 217. Mexico IL-12 Receptor Antagonist Market Size, by Subcutaneous Injection, 2017-2032 (USD Million)
  • TABLE 218. Mexico IL-12 Receptor Antagonist Market Size, by Form, 2017-2032 (USD Million)
  • TABLE 219. Mexico IL-12 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 220. Mexico IL-12 Receptor Antagonist Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 221. Mexico IL-12 Receptor Antagonist Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 222. Mexico IL-12 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 223. Brazil IL-12 Receptor Antagonist Market Size, 2017-2032 (USD Million)
  • TABLE 224. Brazil IL-12 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 225. Brazil IL-12 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 226. Brazil IL-12 Receptor Antagonist Market Size, by Subcutaneous Injection, 2017-2032 (USD Million)
  • TABLE 227. Brazil IL-12 Receptor Antagonist Market Size, by Form, 2017-2032 (USD Million)
  • TABLE 228. Brazil IL-12 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 229. Brazil IL-12 Receptor Antagonist Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 230. Brazil IL-12 Receptor Antagonist Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 231. Brazil IL-12 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 232. United Kingdom IL-12 Receptor Antagonist Market Size, 2017-2032 (USD Million)
  • TABLE 233. United Kingdom IL-12 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 234. United Kingdom IL-12 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 235. United Kingdom IL-12 Receptor Antagonist Market Size, by Subcutaneous Injection, 2017-2032 (USD Million)
  • TABLE 236. United Kingdom IL-12 Receptor Antagonist Market Size, by Form, 2017-2032 (USD Million)
  • TABLE 237. United Kingdom IL-12 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 238. United Kingdom IL-12 Receptor Antagonist Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 239. United Kingdom IL-12 Receptor Antagonist Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 240. United Kingdom IL-12 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 241. Germany IL-12 Receptor Antagonist Market Size, 2017-2032 (USD Million)
  • TABLE 242. Germany IL-12 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 243. Germany IL-12 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 244. Germany IL-12 Receptor Antagonist Market Size, by Subcutaneous Injection, 2017-2032 (USD Million)
  • TABLE 245. Germany IL-12 Receptor Antagonist Market Size, by Form, 2017-2032 (USD Million)
  • TABLE 246. Germany IL-12 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 247. Germany IL-12 Receptor Antagonist Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 248. Germany IL-12 Receptor Antagonist Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 249. Germany IL-12 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 250. France IL-12 Receptor Antagonist Market Size, 2017-2032 (USD Million)
  • TABLE 251. France IL-12 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 252. France IL-12 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 253. France IL-12 Receptor Antagonist Market Size, by Subcutaneous Injection, 2017-2032 (USD Million)
  • TABLE 254. France IL-12 Receptor Antagonist Market Size, by Form, 2017-2032 (USD Million)
  • TABLE 255. France IL-12 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 256. France IL-12 Receptor Antagonist Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 257. France IL-12 Receptor Antagonist Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 258. France IL-12 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 259. Russia IL-12 Receptor Antagonist Market Size, 2017-2032 (USD Million)
  • TABLE 260. Russia IL-12 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 261. Russia IL-12 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 262. Russia IL-12 Receptor Antagonist Market Size, by Subcutaneous Injection, 2017-2032 (USD Million)
  • TABLE 263. Russia IL-12 Receptor Antagonist Market Size, by Form, 2017-2032 (USD Million)
  • TABLE 264. Russia IL-12 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 265. Russia IL-12 Receptor Antagonist Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 266. Russia IL-12 Receptor Antagonist Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 267. Russia IL-12 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 268. Italy IL-12 Receptor Antagonist Market Size, 2017-2032 (USD Million)
  • TABLE 269. Italy IL-12 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 270. Italy IL-12 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 271. Italy IL-12 Receptor Antagonist Market Size, by Subcutaneous Injection, 2017-2032 (USD Million)
  • TABLE 272. Italy IL-12 Receptor Antagonist Market Size, by Form, 2017-2032 (USD Million)
  • TABLE 273. Italy IL-12 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 274. Italy IL-12 Receptor Antagonist Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 275. Italy IL-12 Receptor Antagonist Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 276. Italy IL-12 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 277. Spain IL-12 Receptor Antagonist Market Size, 2017-2032 (USD Million)
  • TABLE 278. Spain IL-12 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 279. Spain IL-12 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 280. Spain IL-12 Receptor Antagonist Market Size, by Subcutaneous Injection, 2017-2032 (USD Million)
  • TABLE 281. Spain IL-12 Receptor Antagonist Market Size, by Form, 2017-2032 (USD Million)
  • TABLE 282. Spain IL-12 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 283. Spain IL-12 Receptor Antagonist Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 284. Spain IL-12 Receptor Antagonist Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 285. Spain IL-12 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 286. China IL-12 Receptor Antagonist Market Size, 2017-2032 (USD Million)
  • TABLE 287. China IL-12 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 288. China IL-12 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 289. China IL-12 Receptor Antagonist Market Size, by Subcutaneous Injection, 2017-2032 (USD Million)
  • TABLE 290. China IL-12 Receptor Antagonist Market Size, by Form, 2017-2032 (USD Million)
  • TABLE 291. China IL-12 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 292. China IL-12 Receptor Antagonist Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 293. China IL-12 Receptor Antagonist Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 294. China IL-12 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 295. India IL-12 Receptor Antagonist Market Size, 2017-2032 (USD Million)
  • TABLE 296. India IL-12 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 297. India IL-12 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 298. India IL-12 Receptor Antagonist Market Size, by Subcutaneous Injection, 2017-2032 (USD Million)
  • TABLE 299. India IL-12 Receptor Antagonist Market Size, by Form, 2017-2032 (USD Million)
  • TABLE 300. India IL-12 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 301. India IL-12 Receptor Antagonist Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 302. India IL-12 Receptor Antagonist Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 303. India IL-12 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 304. Japan IL-12 Receptor Antagonist Market Size, 2017-2032 (USD Million)
  • TABLE 305. Japan IL-12 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 306. Japan IL-12 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 307. Japan IL-12 Receptor Antagonist Market Size, by Subcutaneous Injection, 2017-2032 (USD Million)
  • TABLE 308. Japan IL-12 Receptor Antagonist Market Size, by Form, 2017-2032 (USD Million)
  • TABLE 309. Japan IL-12 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 310. Japan IL-12 Receptor Antagonist Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 311. Japan IL-12 Receptor Antagonist Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 312. Japan IL-12 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 313. Australia IL-12 Receptor Antagonist Market Size, 2017-2032 (USD Million)
  • TABLE 314. Australia IL-12 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 315. Australia IL-12 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 316. Australia IL-12 Receptor Antagonist Market Size, by Subcutaneous Injection, 2017-2032 (USD Million)
  • TABLE 317. Australia IL-12 Receptor Antagonist Market Size, by Form, 2017-2032 (USD Million)
  • TABLE 318. Australia IL-12 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 319. Australia IL-12 Receptor Antagonist Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 320. Australia IL-12 Receptor Antagonist Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 321. Australia IL-12 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 322. South Korea IL-12 Receptor Antagonist Market Size, 2017-2032 (USD Million)
  • TABLE 323. South Korea IL-12 Receptor Antagonist Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 324. South Korea IL-12 Receptor Antagonist Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 325. South Korea IL-12 Receptor Antagonist Market Size, by Subcutaneous Injection, 2017-2032 (USD Million)
  • TABLE 326. South Korea IL-12 Receptor Antagonist Market Size, by Form, 2017-2032 (USD Million)
  • TABLE 327. South Korea IL-12 Receptor Antagonist Market Size, by Patient Age Group, 2017-2032 (USD Million)
  • TABLE 328. South Korea IL-12 Receptor Antagonist Market Size, by Dosage Strength, 2017-2032 (USD Million)
  • TABLE 329. South Korea IL-12 Receptor Antagonist Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 330. South Korea IL-12 Receptor Antagonist Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 331. Global IL-12 Receptor Antagonist Market Share, by Key Player, 2025
  • TABLE 332. Global IL-12 Receptor Antagonist Market, Key Experts